• Simple at-home device to increase the sensitivity of breast self-examinations
  • Early detection of breast cancer saves lives
  • Breast cancer accounts for 1 in 3 new cases of cancer in women every year

IRVINE, Calif., July 14. 10, 2022 (GLOBE NEWSWIRE) — Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) today announced that under a general merchandise supplier agreement with Walmart, the company is aware® The breast self-examination device will now be sold in Walmart’s retail system. Biomerica just shipped its first orders of Aware® product to Walmart, and Walmart will initially begin selling the product through its US online sales channel (https://www.walmart.com/ip/seort/395477102).

Biomerica is also in the final stages of working with Walmart to stock and sell the Aware® produced in Walmart stores in the United States In addition, the Company is in negotiations with other partners for the distribution of the Aware® Breast self-examination product in markets outside the United States

Breast cancer is the most common cancer in women. Unfortunately, every woman is potentially at risk, as more than 70% of women diagnosed have no family history of breast cancer. Currently, there is no way to prevent breast cancer. Early detection of the disease is therefore the key to effective treatment. Early detection greatly improves the chances that breast cancer can be successfully diagnosed and treated. Survival rates reach 99% when the cancer is detected early and is still localized in the breast. However, if the cancer has spread to regional lymph nodes, the 5-year survival rate is 86%. [1,2]

Around 80% of breast cancers are detected because women themselves notice changes in their breasts, highlighting the important role each woman can play in her own health. However, a breast self-examination (BSE) does not replace regular medical visits and periodic ultrasounds or mammograms. All three steps are important for detecting breast cancer at an early stage. The relevance of early detection cannot be overstated.

Biomerica’s FDA cleared Aware® The Breast Self-Examination Device is a revolutionary way for women to improve tactile sensitivity to breast tissue changes or irregularities, making breast self-exams easy and convenient. The Conscious® can facilitate effective self-examination and can serve as a reminder to perform a monthly breast self-examination.

In a study by Kawasaki University Medical Hospital using the Aware® device, the study concluded that the Aware® was “a very effective instrument for the early detection of breast changes”. The study included 832 patients with breast cancer, fibroids, mastitis and non-tumor conditions. [3]

Zack Irani, CEO of Biomerica, said, “Breast cancer treatment success is dramatically improved by early detection. Our unique product provides a tool to help women potentially detect early breast abnormalities. As one of the largest retail companies in the world, Walmart provides unparalleled visibility and distribution for this potentially lifesaving product. We look forward to supporting Walmart in rolling out the product, ensuring that as many women as possible have access to this product.

For more information on Aware® Breast self-examination product, please visit https://AwareBSE.com

About Biomerica (NASDAQ: BMRA)

Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (home and doctor’s offices) and in hospital settings. /clinical. laboratories for the detection and/or treatment of medical conditions and diseases. The Company’s products are designed to improve people’s health and well-being, while reducing total healthcare costs. Biomerica is primarily focused on gastrointestinal and inflammatory diseases for which the company has several diagnostic and therapeutic products in development.

  1. https://www.webmd.com/breast-cancer/guide/breast-cancer-survival-rates. Accessed on July 08, 2022
  2. https://www.cancer.net/cancer-types/breast-cancer/statistics. Accessed on July 08, 2022
  3. Sonoo H, Sai T, Maesaki S (1992) Breast self-examination (in Japanese). Geka (surgery) 54: 574–581.

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Certain information included in this press release (as well as information included in oral or other written statements made or to be made by Biomerica) contains forward-looking statements, such as statements regarding the effectiveness of Aware® Breast self-examination device and other tests, FDA clearance of company products, offer and sale possible online and/or in-store from Aware® Breast self-examination device at Walmart and other potential distributors and retailers, timeliness of test results, negotiations with international distribution partners, uniqueness of the company’s products, accuracy of test results of products, the price of the Company’s test kits, the demand for domestic or international orders, the potential revenues from the sale of current or future products, the availability of the Company’s Aware® Breast self-examination device and other test kits, and patent protection on any of the company’s products or technologies. This forward-looking information involves significant risks and uncertainties that could materially affect anticipated results in the future, including, without limitation: results of studies testing the effectiveness of tests and other products of the society ; the regulatory approvals necessary before the commercialization of any of the Company’s products; the availability of test kits and other Company products; the capacity, resources and other constraints of our suppliers; dependence on our third-party manufacturers; reliance on international shipping carriers; government import/export regulations; demand for our various tests and other products; competition from other similar products and from competitors with significantly greater financial and other resources; government virus control regulations that make it difficult or impossible for the company to maintain its current operations; the Company’s ability to comply with current and future regulations in the countries where our products are manufactured and sold; and the Company’s ability to obtain patent protection on all aspects of its rapid test technologies. Accordingly, these results may differ materially from those expressed in forward-looking statements made by or on behalf of Biomerica. In addition, potential risks and uncertainties include, among others, fluctuations in the Company’s results of operations due to its business model and expansion plans, downturns in international and/or domestic economies, the Company’s ability to raise additional capital, the competitive environment in which the Company will compete and the Company’s dependence on strategic relationships. The Company undertakes no obligation to update any forward-looking statements after the date of this release.

Corporate Contact:

John Nesbett/Jennifer Belodeau
IMS Investor Relations
203.972.9200
biomerica@imsinvestorrelations.com

Source: Biomerica, Inc.